Surface modified magnetic nanoparticles for immuno-gene therapy of murine mammary adenocarcinoma

Biomaterials

Volumn 33, Issue 17, 2012, Pages 4379-4391

  Prijic, Sara ^a   Prosen, Lara ^a   Cemazar, Maja ^b,e   Scancar, Janez ^c   Romih, Rok ^d   Lavrencak, Jaka ^b   Bregar, Vladimir B ^a   Coer, Andrej ^e   Krzan, Mojca ^d   Znidarsic, Andrej ^a   Sersa, Gregor ^b  

^a KOLEKTOR GROUP D O O   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c JO EF STEFAN INSTITUTE   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e UNIVERSITY OF PRIMORSKA   (Slovenia)

Author keywords

Cytokine; Gene therapy; Gene transfer; Magnetism; Nanoparticles; Polyacrylic acid

Indexed keywords

ANTITUMOR EFFECT; CYTOKINES; EXTERNAL MAGNETIC FIELD; IMMUNE RESPONSE; INTERLEUKIN-12; MAGNETIC NANOPARTICLES; MAGNETOFECTION; PLASMID DNA; POLYACRYLIC ACIDS; POLYETHYLENIMINES; REPORTER GENE; SOMATIC CELLS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; SURFACE-MODIFIED; TRANSFECTION EFFICIENCY;

DISEASES; ENCODING (SYMBOLS); GENE ENCODING; GENE THERAPY; GENE TRANSFER; MAGNETIC FIELDS; MAGNETISM; NANOMAGNETICS; NANOPARTICLES; NUCLEIC ACIDS; SUPERPARAMAGNETISM; TUMORS;

BIOMOLECULES;

INTERLEUKIN 12; PLASMID DNA; POLYACRYLIC ACID; POLYETHYLENEIMINE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE POLYACRYLIC ACID POLYETHYLENIMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOGENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SOMATIC CELL;

ACRYLIC RESINS; ADENOCARCINOMA; ANIMALS; BODY WEIGHT; CELL DEATH; CELL LINE; CELL LINE, TUMOR; DNA; ENDOCYTOSIS; FEMALE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-12; MAGNETITE NANOPARTICLES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMIDS; POLYETHYLENEIMINE; SURFACE PROPERTIES; TISSUE DISTRIBUTION; TRANSFECTION;

MURINAE; MUS;

EID: 84858865009     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.02.061     Document Type: Article

References (53)

1. Mikhaylov G., Mikac U., Magaeva A.A., Itin V.I., Naiden E.P., Psakhye I., et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol 2011, 6:594-602.
2. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
3. Lin M.M., Kim dK., El Haj A.J., Dobson J. Development of superparamagnetic iron oxide nanoparticles (SPIONS) for translation to clinical applications. IEEE Trans Nanobioscience 2008, 7:298-305.
4. Hofmann-Amtenbrink M., Hofmann H., Montet X. Superparamagnetic nanoparticles - a tool for early diagnostics. Swiss Med Wkly 2010, 140:w13081.
5. Sanchez-Antequera Y., Mykhaylyk O., van Til N.P., Cengizeroglu A., de Jong J.H., Huston M.W., et al. Magselectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. Blood 2011, 117:e171-e181.
6. Chen B., Wu W., Wang X. Magnetic iron oxide nanoparticles for tumor-targeted therapy. Curr Cancer Drug Targets 2011, 11:184-189.
7. Prijic S., Sersa G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol Oncol 2011, 45:1-16.
8. Scherer F., Anton M., Schillinger U., Henke J., Bergemann C., Krüger A., et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002, 9:102-109.
9. Plank C., Zelphati O., Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-Progress and prospects. Adv Drug Deliv Rev 2011, 63:1300-1331.
10. Krötz F., Sohn H.Y., Gloe T., Plank C., Pohl U. Magnetofection potentiates gene delivery to cultured endothelial cells. J Vasc Res 2003, 40:425-434.
11. Krötz F., de Wit C., Sohn H.Y., Zahler S., Gloe T., Pohl U., et al. Magnetofection-a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003, 7:700-710.
12. Kamau S.W., Hassa P.O., Steitz B., Petri-Fink A., Hofmann H., Hofmann-Amtenbrink M., et al. Enhancement of the efficiency of non-viral gene delivery by application of pulsed magnetic field. Nucleic Acids Res 2006, 34:e40.
13. Xenariou S., Griesenbach U., Ferrari S., Dean P., Scheule R.K., Cheng S.H., et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006, 13:1545-1552.
14. Jahnke A., Hirschberger J., Fischer C., Brill T., Köstlin R., Plank C., et al. Intra-tumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A Physiol Pathol Clin Med 2007, 54:599-606.
15. Lee C.H., Kim E.Y., Jeon K., Tae J.C., Lee K.S., Kim Y.O., et al. Simple, efficient, and reproducible gene transfection of mouse embryonic stem cells by magnetofection. Stem Cells Dev 2008, 17:133-141.
16. Hüttinger C., Hirschberger J., Jahnke A., Köstlin R., Brill T., Plank C., et al. Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial. J Gene Med 2008, 10:655-667.
17. Mykhaylyk O., Zelphati O., Hammerschmid E., Anton M., Rosenecker J., Plank C. Recent advances in magnetofection and its potential to deliver siRNAs in vitro. Methods Mol Biol 2009, 487:111-146.
18. Sapet C., Laurent N., de Chevigny A., Le Gourrierec L., Bertosio E., Zelphati O., et al. High transfection efficiency of neural stem cells with magnetofection. Biotechniques 2011, 50:187-189.
19. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995, 92:7297-7301.
20. Wang X.L., Zhou L.Z., Ma Y.J., Li X., Gu H.C. Control of aggregate size of polyethyleneimine-coated magnetic nanoparticles for magnetofection. Nano Res 2009, 2:365-372.
21. Moghimi S.M., Symonds P., Murray J.C., Hunter A.C., Debska G., Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005, 11:990-995.
22. Stayton P.S., El-Sayed M.E., Murthy N., Bulmus V., Lackey C., Cheung C., et al. 'Smart' delivery systems for biomolecular therapeutics. Orthod Craniofac Res 2005, 8:219-225.
23. Trubetskoy V.S., Wong S.C., Subbotin V., Budker V.G., Loomis A., Hagstrom J.E., et al. Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther 2003, 10:261-271.
24. Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn 1981, 17:1247-1248.
25. Holzwarth U., Gibson N. The Scherrer equation versus the 'Debye-Scherrer equation'. Nat Nanotechnol 2011, 6:534.
26. Todorovic V., Sersa G., Mlakar V., Glavac D., Flisar K., Cemazar M. Metastatic potential of melanoma cells is not affected by electrochemotherapy. Melanoma Res 2011, 21:196-205.
27. Pavlin D., Cemazar M., Kamensek U., Tozon N., Pogacnik A., Sersa G. Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther 2009, 8:2114-2122.
28. Bancroft J., Cook H. Manual of histological techniques and their diagnostic application 1994, Churchill Livingstone, Edinburgh, New York. 1st ed.
29. Rakhmilevich A.L., Janssen K., Hao Z., Sondel P.M., Yang N.S. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther 2000, 7:826-838.
30. Cemazar M., Golzio M., Sersa G., Hojman P., Kranjc S., Mesojednik S., et al. Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther 2009, 16:635-644.
31. Cemazar M., Golzio M., Sersa G., Rols M.P., Teissié J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand?. Curr Pharm Des 2006, 12:3817-3825.
32. Li S., Zhang X., Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 2002, 94:762-768.
33. Di Marco M., Sadun C., Port M., Guilbert I., Couvreur P., Dubernet C. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine 2007, 2:609-622.
34. Prijic S., Scancar J., Romih R., Cemazar M., Bregar V.B., Znidarsic A., et al. Increased cellular uptake of biocompatible superparamagnetic iron oxide nanoparticles into malignant cells by an external magnetic field. J Membr Biol 2010, 236:167-179.
35. Gajdosíková A., Gajdosík A., Koneracká M., Závisová V., Stvrtina S., Krchnárová V., et al. Acute toxicity of magnetic nanoparticles in mice. Neuro Endocrinol Lett 2006, 27(Suppl. 2):96-99.
36. Wu W., Chen B., Cheng J., Wang J., Xu W., Liu L., et al. Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine 2010, 5:1079-1084.
37. Li Y., Liu J., Zhong Y., Zhang J., Wang Z., Wang L., et al. Biocompatibility of Fe3O4@Au composite magnetic nanoparticles in vitro and in vivo. Int J Nanomedicine 2011, 6:2805-2819.
38. Bacon B.R., Stark D.D., Park C.H., Saini S., Groman E.V., Hahn P.F., et al. Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration. J Lab Clin Med 1987, 110:164-171.
39. Jordan A., Scholz R., Wust P., Schirra H., Thomas S., Schmidt H., et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J Magnetism Magn Mater 1999, 194:185-196.
40. Ma Y.J., Gu H.C. Study on the endocytosis and the internalization mechanism of aminosilane-coated Fe3O4 nanoparticles in vitro. J Mater Sci Mater Med 2007, 18:2145-2149.
41. Godbey W.T., Wu K.K., Mikos A.G. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S A 1999, 96:5177-5181.
42. Cemazar M., Sersa G., Wilson J., Tozer G.M., Hart S.L., Grosel A., et al. Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 2002, 9:399-406.
43. Zuhorn I.S., Hoekstra D. On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question?. J Membr Biol 2002, 189:167-179.
44. Hafez I.M., Maurer N., Cullis P.R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 2001, 8:1188-1196.
45. Namiki Y., Namiki T., Yoshida H., Ishii Y., Tsubota A., Koido S., et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol 2009, 4:598-606.
46. Kievit F.M., Veiseh O., Bhattarai N., Fang C., Gunn J.W., Lee D., et al. PEI-PEG-Chitosan copolymer coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater 2009, 19:2244-2251.
47. Kievit F.M., Veiseh O., Fang C., Bhattarai N., Lee D., Ellenbogen R.G., et al. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 2010, 4:4587-4594.
48. Luo D., Saltzman W.M. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat Biotechnol 2000, 18:893-895.
49. Chertok B., Moffat B.A., David A.E., Yu F., Bergemann C., Ross B.D., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29:487-496.
50. Schmidt W., Schweighoffer T., Herbst E., Maass G., Berger M., Schilcher F., et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci U S A 1995, 92:4711-4714.
51. Tevz G., Kranjc S., Cemazar M., Kamensek U., Coer A., Krzan M., et al. Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009, 11:1125-1137.
52. Kamensek U., Sersa G. Targeted gene therapy in radiotherapy. Radiol Oncol 2008, 42:115-135.
53. Plank C. Nanomedicine: Silence the target. Nat Nanotechnol 2009, 4:544-545.